Related Experiment Video

Updated: Jun 6, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Concise review: stem cells as an emerging platform for antibody therapy of cancer

Richard T Frank1, Joseph Najbauer, Karen S Aboody

  • 1Department of Neurosciences, City of Hope National Medical Center and Beckman Research Institute, Duarte, California 91010-3000, USA. rikfrank@gmail.com

Stem Cells (Dayton, Ohio)
|November 20, 2010
PubMed

Insights

Stem cell-mediated delivery shows promise for improving antibody cancer therapy. This approach may overcome limitations like toxicity and poor tumor penetration, enhancing treatment effectiveness.

Area of Science:

  • Oncology
  • Immunotherapy
  • Biotechnology

Background:

  • Monoclonal antibodies are crucial in cancer therapy.
  • Current antibody therapies face limitations: toxicity, poor tumor penetration, and blood-brain barrier exclusion.
  • These factors restrict treatment efficacy and patient outcomes.

Purpose of the Study:

  • To review the emerging field of stem cell-mediated antibody delivery.
  • To explore how this novel approach can overcome existing limitations in antibody cancer therapy.
  • To highlight the potential of stem cells to enhance antibody delivery and efficacy.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of stem cell properties relevant to drug delivery.
  • Evaluation of stem cell-mediated antibody delivery systems in preclinical cancer models.

Main Results:

  • Stem cells possess inherent properties suitable for targeted drug delivery.
  • Stem cell-mediated delivery can enhance antibody penetration into tumors.
  • This approach shows potential in overcoming the blood-brain barrier for brain tumor treatment.
  • Preclinical data suggest improved therapeutic outcomes with stem cell-assisted antibody delivery.

Conclusions:

  • Stem cell-mediated antibody delivery represents a promising strategy to improve cancer therapy.
  • This approach offers a potential solution to key challenges limiting current monoclonal antibody treatments.
  • Further research and clinical translation are warranted to fully realize the potential of this innovative therapy.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their access...
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...